Movano (NASDAQ:MOVE – Get Free Report) released its earnings results on Friday. The technology company reported ($5.12) earnings per share for the quarter, missing the consensus estimate of ($3.17) by ($1.95), Zacks reports.
Here are the key takeaways from Movano’s conference call:
- Contracted annualized recurring revenue on live compute reached approximately $22 million as of August 2026, supported by fixed-term, take-or-pay contracts. The company also announced a Blackwell expansion funded through debt, customer prepayment, and existing cash.
- Second-quarter revenue was only $3.8 million, while adjusted EBITDA was negative $3.2 million and net loss was $12.8 million. Management emphasized that revenue depends on capacity being live and handed over, so signed contracts do not immediately translate into reported revenue.
- Corvex Token Factory version 1 entered closed alpha, with additional releases planned for the third and fourth quarters. The company is positioning the platform around lower-cost open-weight model inference, automation, reliability, and confidential computing, but the products remain early-stage.
- Management acknowledged substantial execution and financing risks, including the need for significant additional capital, customer concentration, unremediated material weaknesses in internal controls, and ongoing non-cash stock compensation charges. Following preferred-stock conversions, the company had approximately 56.6 million common shares on an as-converted basis, while a resale registration covers up to 53.4 million shares held by existing investors.
Movano Price Performance
Shares of MOVE traded up $0.57 during mid-day trading on Friday, reaching $11.72. The company had a trading volume of 165,560 shares, compared to its average volume of 445,334. The firm has a fifty day simple moving average of $16.17 and a 200-day simple moving average of $15.70. Movano has a fifty-two week low of $3.44 and a fifty-two week high of $26.72. The company has a quick ratio of 2.04, a current ratio of 2.14 and a debt-to-equity ratio of 4.28.
Key Stories Impacting Movano
- Positive Sentiment: The stock’s resilience after the earnings release may indicate that investors had already discounted substantial losses or are focused on Movano’s longer-term wearable-health technology opportunity rather than the quarter’s results.
- Neutral Sentiment: Broader market sentiment was soft as the S&P 500 and Nasdaq 100 declined following weaker consumer sentiment and retail-sales data. This creates a less supportive backdrop for speculative technology stocks, although the market weakness was not specific to Movano. Stock Market Today: SPY, QQQ Stumble as Consumer Sentiment Slips and Retail Sales Slide
- Negative Sentiment: Movano reported a quarterly loss of $5.12 per share, missing the analyst consensus estimate of a $3.17 loss by $1.95. The sizable earnings miss reinforces concerns about cash burn, the company’s path to profitability and the need for potential future financing. Movano quarterly earnings press release
Analyst Ratings Changes
Separately, Wall Street Zen raised shares of Movano from a “sell” rating to a “hold” rating in a research note on Sunday, May 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.
Check Out Our Latest Analysis on Movano
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in Movano stock. Citadel Advisors LLC bought a new stake in Movano Inc. (NASDAQ:MOVE – Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 49,262 shares of the technology company’s stock, valued at approximately $28,000. Citadel Advisors LLC owned about 5.94% of Movano at the end of the most recent quarter. Hedge funds and other institutional investors own 16.64% of the company’s stock.
About Movano
Movano Health, Inc (NASDAQ: MOVE) is a health technology company focused on developing wearable devices for continuous biometric monitoring. The company’s core mission is to provide accessible, real-time health insights through noninvasive sensors, enabling individuals and care teams to track vital signs and physiological trends outside of traditional clinical settings.
Movano’s flagship product is a biometric monitoring ring designed to measure parameters such as heart rate, blood oxygen saturation, skin temperature, and sleep quality.
Read More
- Five stocks we like better than Movano
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Movano Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Movano and related companies with MarketBeat.com's FREE daily email newsletter.
